Adults who were expected to have an ICU stay of at least three days and who had persistent hyperglycemia for up to six hours after admission, were receiving insulin, or both had a peripheral venous catheter placed and connected to a continuous
The score, which was based on cardiac troponin, N-terminal pro-B-type natriuretic peptide, C-reactive protein, and electrocardiography, could be used to target specific therapies to the highest-risk patients, study authors said.
Continuous glucose monitoring (CGM) was associated with improved HbA1c levels among adolescents and young adults in one trial and less hypoglycemia among older adults in another.
A randomized trial found equivalent improvements in visual acuity at two years with either therapy but identified some differences in outcomes that could help patients and clinicians choose a treatment method.
Risk factor control was more strongly associated with mortality risk among patients with cardiorenal disease than those without, according to a retrospective British study.
In a recent study, a serum C-peptide testing program resulted in reclassification of the cause of diabetes in about 7% of the cohort tested at one diabetes center in Scotland. Reclassification was most likely in those diagnosed at age 30 years or
study. They wrote, “The current study further highlights the potential futility of aggressive diabetes screening in older adults given the very low rates of diabetes progression among those with prediabetes.”.
A pooled analysis of three randomized clinical trials found reductions in major adverse cardiac or cerebrovascular events after percutaneous coronary intervention (PCI) at 3.9-year follow-up only in patients with low-density lipoprotein (LDL)
The advent of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists could reduce cardiovascular adverse events and progression to end-stage kidney disease, the American Heart Association (AHA) scientific statement
The authors of the retrospective study called for additional research on the pathogenesis of acute kidney injury (AKI) and the associated risk factors, such as medications, in diabetic patients.